Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your Phone's microphone could soon screen for lung disease

NCT ID NCT07457073

Diagnosis Sponsor: Sir Run Run Shaw Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence program can detect chronic obstructive pulmonary disease (COPD) by analyzing cough sounds recorded on a smartphone. Researchers will collect cough recordings and medical data from 3,000 adults in China, both with and without COPD, to train and validate the AI model. If accurate, this could offer a low-cost, non-invasive screening option for COPD, especially in primary care settings where standard breathing tests are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
artificial intelligence analysis of cough sounds
What this could lead to
If successful, this could provide a simple, affordable way to screen for COPD using just a smartphone recording, especially in places without access to standard breathing tests.
What could go wrong
The AI model is still being developed and validated, so its accuracy in real-world settings is not yet proven. The study is limited to one region in China, so results may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will prospectively enroll approximately 3,000 adult participants at Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University (Hangzhou, China) - a tertiary academic medical center. This single-center cohort will serve as the primary dataset for development and internal validation of an artificial intelligence (AI)-based cough sound model for COPD screening. The cohort will include: Adults aged ≥18 years with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) based on post-bronchodilator spirometry (FEV₁/FVC \< 0.70, per GOLD 2024 criteria), and Non-COPD controls who undergo comprehensive clinical evaluation and spirometry confirming the absence of airflow limitation (FEV₁/FVC ≥ 0.70) and no clinical diagnosis of COPD.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosed with COPD per GOLD 2024 criteria OR clinically confirmed as non-COPD （for COPD cohort） * Able to perform a voluntary cough on instruction * Provides informed consent (or through legally authorized representative/witness if illiterate) Exclusion Criteria: * Unstable angina or severe arrhythmia * Severe fatigue due to advanced heart failure or chemotherapy * Progressive neuromuscular disease * Pregnancy or lactation * Life expectancy \<6 months * Unable to complete spirometry or study procedures * Other vulnerable populations (e.g., active psychiatric illness, cognitive impairment, critically ill)-except elderly/illiterate individuals who are protected via consent safeguards

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

Contacts and locations

Locations

  • Sir Run Run shaw Hospital Zhejiang University

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.